Organon & Co. Faces Securities Class Action Lawsuit Over Dividend Misrepresentation; Shareholder Deadline Approaches

Reuters

06/18

Organon & Co. Faces Securities Class Action Lawsuit Over Dividend Misrepresentation; Shareholder Deadline Approaches

Organon & Co., a healthcare company based in Jersey City, NJ, is facing a securities class action lawsuit filed on behalf of investors who acquired the company's securities between October 31, 2024, and April 30, 2025. The lawsuit is in response to an unexpected change in the company's dividend payout policy following its acquisition of Dermavant for $1.2 billion. Despite assurances from Organon that the dividend would remain its top capital allocation priority, the company announced a reduction in its dividend from $0.28 to $0.02 per share on May 1, 2025, to focus on reducing debt. This news led to a significant decline in Organon's stock price, dropping approximately 27% to $9.45 per share. Investors who purchased Organon securities during the specified period have until July 22, 2025, to seek appointment as a lead plaintiff representative in the case. The litigation is being handled by Berger Montague PC, a firm known for its expertise in securities class action lawsuits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Newsfile (Ref. ID: 255916) on June 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544297030"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544297030\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544297030?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-18 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544297030","market":"nz","top_or_hot":-1,"title":"Organon & Co. Faces Securities Class Action Lawsuit Over Dividend Misrepresentation; Shareholder Deadline Approaches","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Organon &amp; Co. Faces Securities Class Action Lawsuit Over Dividend Misrepresentation; Shareholder Deadline Approaches\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Organon &amp; Co., a healthcare company based in Jersey City, NJ, is facing a securities class action lawsuit filed on behalf of investors who acquired the company's securities between October 31, 2024, and April 30, 2025. The lawsuit is in response to an unexpected change in the company's dividend payout policy following its acquisition of Dermavant for $1.2 billion. Despite assurances from Organon that the dividend would remain its top capital allocation priority, the company announced a reduction in its dividend from $0.28 to $0.02 per share on May 1, 2025, to focus on reducing debt. This news led to a significant decline in Organon's stock price, dropping approximately 27% to $9.45 per share. Investors who purchased Organon securities during the specified period have until July 22, 2025, to seek appointment as a lead plaintiff representative in the case. The litigation is being handled by Berger Montague PC, a firm known for its expertise in securities class action lawsuits.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon &amp; Co. published the original content used to generate this news brief via Newsfile (Ref. ID: 255916) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Organon & Co. Faces Securities Class Action Lawsuit Over Dividend Misrepresentation; Shareholder Deadline Approaches</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrganon & Co. Faces Securities Class Action Lawsuit Over Dividend Misrepresentation; Shareholder Deadline Approaches\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-18 21:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Organon &amp; Co. Faces Securities Class Action Lawsuit Over Dividend Misrepresentation; Shareholder Deadline Approaches\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Organon &amp; Co., a healthcare company based in Jersey City, NJ, is facing a securities class action lawsuit filed on behalf of investors who acquired the company's securities between October 31, 2024, and April 30, 2025. The lawsuit is in response to an unexpected change in the company's dividend payout policy following its acquisition of Dermavant for $1.2 billion. Despite assurances from Organon that the dividend would remain its top capital allocation priority, the company announced a reduction in its dividend from $0.28 to $0.02 per share on May 1, 2025, to focus on reducing debt. This news led to a significant decline in Organon's stock price, dropping approximately 27% to $9.45 per share. Investors who purchased Organon securities during the specified period have until July 22, 2025, to seek appointment as a lead plaintiff representative in the case. The litigation is being handled by Berger Montague PC, a firm known for its expertise in securities class action lawsuits.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon &amp; Co. published the original content used to generate this news brief via Newsfile (Ref. ID: 255916) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDLbfqVg4:1","article_id":"2544297030","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544297030","pubTimestamp":1750252016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Organon & Co., a healthcare company based in Jersey City, NJ, is facing a securities class action lawsuit filed on behalf of investors who acquired the company's securities between October 31, 2024, and April 30, 2025. The lawsuit is in response to an unexpected change in the company's dividend payout policy following its acquisition of Dermavant for $1.2 billion. Despite assurances from Organon that the dividend would remain its top capital allocation priority, the company announced a reduction in its dividend from $0.28 to $0.02 per share on May 1, 2025, to focus on reducing debt. This news led to a significant decline in Organon's stock price, dropping approximately 27% to $9.45 per share. Investors who purchased Organon securities during the specified period have until July 22, 2025, to seek appointment as a lead plaintiff representative in the case. The litigation is being handled by Berger Montague PC, a firm known for its expertise in securities class action lawsuits.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","OGN":"Organon & Co","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4559":"巴菲特持仓","BK4007":"制药"},"translate_title":"Organon&Co.因股息虚假陈述面临证券集体诉讼；股东截止日期临近","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OGN":0.9},"content_text":"Organon & Co. Faces Securities Class Action Lawsuit Over Dividend Misrepresentation; Shareholder Deadline Approaches\n    \n\n        Organon & Co., a healthcare company based in Jersey City, NJ, is facing a securities class action lawsuit filed on behalf of investors who acquired the company's securities between October 31, 2024, and April 30, 2025. The lawsuit is in response to an unexpected change in the company's dividend payout policy following its acquisition of Dermavant for $1.2 billion. Despite assurances from Organon that the dividend would remain its top capital allocation priority, the company announced a reduction in its dividend from $0.28 to $0.02 per share on May 1, 2025, to focus on reducing debt. This news led to a significant decline in Organon's stock price, dropping approximately 27% to $9.45 per share. Investors who purchased Organon securities during the specified period have until July 22, 2025, to seek appointment as a lead plaintiff representative in the case. The litigation is being handled by Berger Montague PC, a firm known for its expertise in securities class action lawsuits.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Newsfile (Ref. ID: 255916) on June 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}